<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>77</patient-age><report-id>PHHY2012FR113154</report-id><gender>unknown</gender><reactions><reaction>Diabetes</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>AMN107</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>EPREX</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DIFFU K</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PARIET</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CLARITYNE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Anaemia</indication><indication>Hypokalaemia</indication><indication>Gastrooesophageal reflux disease</indication></indications><patient-age>77</patient-age><outcomes/><country>France</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053131_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133931</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012FR113154</safetyreportid>
		<primarysourcecountry>FR</primarysourcecountry>
		<occurcountry>FR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-10</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-05</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-05</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012FR113154</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="1">Physician</qualification>
			<sponsorstudynumb>CAMN107AFR06</sponsorstudynumb>
			<observestudytype>2</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>77</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientweight>75</patientweight>
			<patientheight>173</patientheight>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypokalaemia</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Anaemia</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Gastrooesophageal reflux disease</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Diabetes</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Diabetes</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Diabetes mellitus</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121016</reactionstartdate>
				<reactionfirsttime>43</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>Blood glucose</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>AMN107</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>400 mg, BID</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-09-04</drugstartdate>
				<drugstartperiod>43</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diabetes mellitus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diabetes mellitus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>EPREX</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>40000</drugstructuredosagenumb>
				<drugstructuredosageunit code="025"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="802">Month</drugintervaldosagedefinition>
				<drugdosagetext>40000 IU, QMO</drugdosagetext>
				<drugadministrationroute code="042">Intravenous (not otherwise specified)</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Anaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-08</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>EPOETIN ALFA</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>DIFFU K</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypokalaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-06-28</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-10-08</drugenddate>
				<drugtreatmentduration>469</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>POTASSIUM CHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>PARIET</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>20</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>20 mg, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Gastrooesophageal reflux disease</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>RABEPRAZOLE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CLARITYNE</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LORATADINE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012FR113154, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>PMS report from an investigator received on 05 Dec 2012. This report refers to a 77-year old patient (centre number: 07, patient number: 05) enrolled in the observational study <Semaphore x="2603822" class="Procedure" value="Target Lesion Identification" score="1.00" ID="C94520">TARGET </Semaphore>RMC (CAMN107AFR06) to evaluate <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore><Semaphore x="1803898" class="Disease or Finding" value="Complete Remission" score="1.00" ID="C4870">response - rate of complete molecular response </Semaphore>- after 18 and 24 months of <Semaphore x="2502709" class="Procedure" value="Second Line Treatment" score="1.00" ID="C54350">second line therapy </Semaphore>with <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.93" ID="282225">Tasigna </Semaphore>(<Semaphore x="928154" class="Medicine" value="nilotinib" score="0.87" ID="278855">nilotinib</Semaphore>) in patients with <Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174"><Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174">CML </Semaphore>in chronic phase</Semaphore>. The patientâ€™s medical history included <Semaphore x="1524787" class="Disease or Finding" value="Anemia" score="1.00" ID="C2869">anemia</Semaphore>, gastro <Semaphore x="1965183" class="Disease or Finding" value="Gastroesophageal Reflux" score="1.00" ID="C92560">oesophageal reflux </Semaphore>and <Semaphore x="2039588" class="Disease or Finding" value="Hypokalemia" score="1.00" ID="C37974">hypokalemia </Semaphore>Concomitant medications Eprex (<Semaphore x="535266" class="Medicine" value="Epoetin Alfa" score="0.49" ID="190969">epoetin alfa</Semaphore>), Diffu <Semaphore x="1880026" class="Procedure" value="Electrolyte Measurement" score="0.58" ID="C74946">K </Semaphore>(<Semaphore x="1848940" class="Procedure" value="Dietary Protocol" score="1.00" ID="C93051">potassium </Semaphore><Semaphore x="1771945" class="Procedure" value="Chloride Measurement" score="1.00" ID="C64495">chloride</Semaphore>), Pariet (<Semaphore x="1117626" class="Medicine" value="RABEprazole sodium" score="0.49" ID="249307">rabeprazole <Semaphore x="1880026" class="Procedure" value="Electrolyte Measurement" score="0.58" ID="C74946">sodium</Semaphore></Semaphore>) and Clarityne (<Semaphore x="798398" class="Medicine" value="Loratadine" score="0.49" ID="243030">loratadine</Semaphore>). The patient received <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.93" ID="282225">Tasigna </Semaphore>(<Semaphore x="928154" class="Medicine" value="nilotinib" score="0.87" ID="278855">nilotinib</Semaphore>) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of suboptimal <Semaphore x="1854566" class="Disease or Finding" value="Disease Response" score="1.00" ID="C50995">response </Semaphore>to <Semaphore x="699336" class="Medicine" value="imatinib" score="0.49" ID="252378">imatinib </Semaphore>from 04 Sep 2012, <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>at a dose of 400 mg twice daily. The patient experienced <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes </Semaphore>on 16 Oct 2012. On 16 Oct 2012 the patient started a <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with Galvus (<Semaphore x="1329926" class="Medicine" value="vildagliptin" score="0.49" ID="275888">vildagliptin</Semaphore>) 6 weeks after having started <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.93" ID="282225">Tasigna </Semaphore>(<Semaphore x="928154" class="Medicine" value="nilotinib" score="0.87" ID="278855">nilotinib</Semaphore>). The event <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was reported as condition improved. The causality <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment </Semaphore>for the event <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes </Semaphore>was reported as not suspected with <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.93" ID="282225">Tasigna </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy</Semaphore>.</narrativeincludeclinical>
				<sendercomment>Medical review and assessment complete. Novartis concurs with the investigator's assessment.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>